Life sciences tools company Agilent Technologies (NYSE: A) announced better-than-expected revenue in Q1 CY2026 (fiscal Q2), with sales up 10% year on year to $1.84 billion. The company expects next quarter’s revenue to be around $1.84 billion, close to analysts’ estimates. Its non-GAAP profit of $1.49 per share was 5.8% above analysts’ consensus estimates.
Is now the time to buy A? Find out in our full research report (it’s free for active Edge members).
Agilent (A) Q1 CY2026 Highlights:
- Revenue: $1.84 billion vs analyst estimates of $1.80 billion (10% year-on-year growth, 1.9% beat)
- Adjusted EPS: $1.49 vs analyst estimates of $1.41 (5.8% beat)
- Adjusted EBITDA: $550 million vs analyst estimates of $503.2 million (30% margin, 9.3% beat)
- The company slightly lifted its revenue guidance for the full year to $7.44 billion at the midpoint from $7.4 billion
- Management raised its full-year Adjusted EPS guidance to $6.05 at the midpoint, a 1.3% increase
- Operating Margin: 21.7%, up from 18% in the same quarter last year
- Organic Revenue rose 6.3% year on year (beat)
- Market Capitalization: $32.74 billion
StockStory’s Take
Agilent’s second quarter saw a positive market reaction, underpinned by broad-based revenue growth and notable operating margin expansion. Management credited the quarter’s outperformance to strong demand across key end markets, robust instrument sales, and the benefits of its Ignite operating system. CEO Padraig McDonnell highlighted that “replacement site momentum, innovation-led share gains, and improving operational execution” were central to Agilent’s results, while the company’s strategic pricing initiatives and ongoing productivity efforts further supported profitability.
Looking forward, Agilent’s updated guidance is shaped by healthy demand in pharma, diagnostics, and advanced materials, as well as ongoing operational improvements. Management expects the instrument replacement cycle, upcoming product launches, and synergies from the Biocare acquisition to further support growth. CFO Adam S. Elinoff emphasized that the Ignite operating system will help “absorb inflationary cost pressures” and support margin expansion, while new innovation releases and expanding service offerings are anticipated to drive durable earnings growth.
Key Insights from Management’s Remarks
Management attributed second quarter performance to strong instrument sales, operational efficiencies from Ignite, and favorable momentum in key end markets such as diagnostics, pharma, and advanced materials.
- Instrument replacement cycle tailwind: Agilent’s growth was propelled by high single-digit instrument revenue increases, with low double-digit gains in liquid chromatography (LC), mass spectrometry (LCMS), and gas chromatography (GC). The replacement of aging laboratory equipment and customer demand for advanced features contributed meaningfully, as did share gains in competitive accounts.
- Ignite operating system impact: Operational initiatives under Ignite, including strategic pricing and supply chain agility, delivered over 200 basis points in pricing benefits, fully offset incremental tariffs, and improved productivity. These changes are now structurally embedded, providing ongoing margin support.
- Diagnostics and oncology momentum: Diagnostics and clinical segment revenue increased 11%, driven by strong adoption of the Omnis instrument family and double-digit growth in pathology reagents. Management cited expanding offerings in cancer diagnostics and companion diagnostics as key contributors.
- Semiconductor and advanced materials strength: The chemical and advanced materials (CAM) segment grew 8%, with strong semiconductor demand and capital investments in the Americas fueling momentum. Agilent’s technology leadership in spectroscopy and GC was highlighted as a differentiator in these applications.
- Digital and e-commerce acceleration: Agilent’s digital initiatives led to a 9% increase in new digital orders, especially outside China. The focus on digital sales channels improved customer experience and reduced transaction costs, supporting both top-line growth and operational efficiency.
Drivers of Future Performance
Looking ahead, Agilent’s guidance is driven by continued instrument demand, innovation launches, and the operational benefits of Ignite, while inflationary and geopolitical risks remain considerations.
- Product innovation pipeline: Management is focused on the upcoming launches of advanced mass spectrometry and GC instruments, as well as expanded consumables and software offerings. These launches are expected to strengthen Agilent’s installed base and drive recurring revenue from consumables and services.
- Operational discipline and margin resilience: The Ignite operating system is anticipated to deliver further productivity gains, procurement savings, and supply chain resilience. Management expects these efficiencies to help offset inflationary and logistical pressures, supporting margin expansion even as the company invests in R&D and market growth.
- End-market and geographic diversification: While pharmaceutical and diagnostics growth are key, Agilent’s exposure to advanced materials, forensics, and environmental testing provides multiple revenue streams. Management noted that government funding delays in Asia and headwinds in the food segment may weigh on growth, but overall market and geographic diversity underpin the company’s outlook.
Catalysts in Upcoming Quarters
In future quarters, our team will closely track (1) continued instrument order momentum and the impact of new product launches, (2) realization of operational savings and margin improvement from the Ignite system, and (3) progress on integrating the Biocare acquisition and expanding diagnostics offerings. Additional signposts include stabilization in the food and academic segments and the impact of macroeconomic or geopolitical headwinds on customer capital spending.
Agilent currently trades at $124.87, up from $115.89 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).
Our Favorite Stocks Right Now
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
